25.01.2015 Views

Prescribing in General Practice

Prescribing in General Practice

Prescribing in General Practice

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

<strong>Prescrib<strong>in</strong>g</strong> <strong>in</strong><br />

<strong>General</strong> <strong>Practice</strong><br />

Department of Public Health and Primary Care<br />

Outl<strong>in</strong>e<br />

• <strong>Prescrib<strong>in</strong>g</strong> <strong>in</strong> Ireland<br />

• How to Write a Prescription – regular and<br />

controlled drugs<br />

• Rational <strong>Prescrib<strong>in</strong>g</strong>, Social <strong>Prescrib<strong>in</strong>g</strong>,<br />

Placebos<br />

• Patient Adherence<br />

• The Pharmaceutical Industry<br />

• Case Studies<br />

Introduction<br />

• Aims of Session<br />

– Learn how to write a prescription<br />

– Discuss the pr<strong>in</strong>ciples of rational prescrib<strong>in</strong>g<br />

– Learn where to get unbiased <strong>in</strong>formation<br />

– Discuss the concept of patient adherence<br />

– Discuss the factors that <strong>in</strong>fluence prescrib<strong>in</strong>g<br />

– Discuss the relationship between the pharmaceutical<br />

<strong>in</strong>dustry and doctors<br />

– Review case studies of common prescrib<strong>in</strong>g problems<br />

Introduction<br />

• <strong>Prescrib<strong>in</strong>g</strong> <strong>in</strong> Irish Primary Care<br />

– In what % of consultations is a script issued<br />

– How many items are there <strong>in</strong> the average<br />

prescription<br />

– For the average elderly patient<br />

– How many prescriptions per GMS pt / year<br />

Introduction<br />

• <strong>Prescrib<strong>in</strong>g</strong> <strong>in</strong> Irish Primary Care<br />

– In what % of consultations is a Rx issued 63%<br />

– How many items are there <strong>in</strong> the average<br />

prescription 2<br />

– For the average elderly patient rept Rx 8.8<br />

– How many Rx per GMS pt / year 6.7<br />

<strong>Prescrib<strong>in</strong>g</strong> <strong>in</strong> Ireland<br />

• The GMS System<br />

– Doctor Visit card, GMS card<br />

– Capitation fee per patient on list<br />

– Approx 1/3 of population covered<br />

• Family Drug Refund Scheme (100 euro/ month)<br />

• Long Term Illness Scheme (eg. Diabetes,<br />

Epilepsy)<br />

• Generic / Trade Name<br />

1


Generic v. Brand Names<br />

• Generic <strong>Prescrib<strong>in</strong>g</strong><br />

– Usually cheaper<br />

– Less confusion (most of the time)<br />

– Generic names are <strong>in</strong>ternational – clear exchange of<br />

<strong>in</strong>formation<br />

In Ireland, at present:<br />

– Private patients: pharmacist not obliged to give<br />

cheapest formulation if GP prescribes generically<br />

– GMS patients: government and pharmacists have<br />

agreed prices for various drugs<br />

– Future changes<br />

Generic v. Brand Names<br />

• Brand Name <strong>Prescrib<strong>in</strong>g</strong><br />

– Supports research and development by<br />

pharmaceutical companies<br />

– Familiarity for patients May prejudice<br />

adherence<br />

– Brand names usually shorter, and easier to<br />

remember<br />

– Usually more expensive than generic<br />

– Protected period follow<strong>in</strong>g drug launch: Patent<br />

lasts for 10 years (usually) then comes “offlicence”<br />

Rational <strong>Prescrib<strong>in</strong>g</strong><br />

• Aims of Good <strong>Prescrib<strong>in</strong>g</strong><br />

– Maximise effectiveness<br />

– M<strong>in</strong>imise risk<br />

– M<strong>in</strong>imise cost<br />

– Patient centred<br />

Rational <strong>Prescrib<strong>in</strong>g</strong><br />

• What is it<br />

– <strong>Prescrib<strong>in</strong>g</strong> conforms to consensus op<strong>in</strong>ion of the<br />

current best practice<br />

• How to Prescribe Rationally<br />

– Choice of drug is <strong>in</strong>fluenced by several considerations:<br />

• 1. Is the diagnosis known (HTN v. muscular ach<strong>in</strong>g)<br />

• 2. Is a drug required<br />

• 3. Will it work<br />

• 4. Will it harm the patient<br />

• 5. How much will it cost (see next slide)<br />

• 6. Have all the alternatives been considered<br />

• 7. Is the likely benefit : risk ratio acceptable<br />

Rational <strong>Prescrib<strong>in</strong>g</strong><br />

• Cost of Medication<br />

– Antihypertensives:<br />

• Bendroflumethiazide 2.5mg (100 tabs) - €5<br />

• Atenolol 50mg (30 tabs) - €4.93<br />

• Lis<strong>in</strong>opril 5mg (30 tabs) - €10.31<br />

• Per<strong>in</strong>dopril 5mg (30 tabs) - €18.46<br />

• Candesartan 8mg (28 tabs) - €21.56<br />

– Stat<strong>in</strong> – e.g. pravastat<strong>in</strong><br />

• Lipostat 20mg (28 tabs) - €43.44<br />

• Pravamel 20mg (30 tabs) - €37.58<br />

– Nu-Seals Aspir<strong>in</strong> 75mg (28 tabs) - €2.24<br />

Rational <strong>Prescrib<strong>in</strong>g</strong><br />

• The Responsible Prescriber<br />

– Several duties:<br />

• To ensure that the diagnosis is correct<br />

• To make a positive and correct decision that a drug is<br />

needed, and to know enough about the chosen drug<br />

• To choose a drug appropriate to the patient’s needs<br />

• To consult the patient, and to ensure there is<br />

<strong>in</strong>formed consent<br />

• To expla<strong>in</strong> the patient’s role and to secure his / her<br />

cooperation<br />

• To oversee the course of treatment<br />

• To term<strong>in</strong>ate it when it is no longer needed<br />

2


Rational <strong>Prescrib<strong>in</strong>g</strong><br />

• What do you need before writ<strong>in</strong>g a<br />

prescription<br />

– Cl<strong>in</strong>ical skills<br />

– Knowledge of therapeutics (sources of<br />

<strong>in</strong>formation)<br />

– Communication skills (education, adherence)<br />

Keep<strong>in</strong>g Up To Date<br />

• Sources of Objective Information on Medications<br />

– <strong>Practice</strong> formulary<br />

– Other formularies – MIMS, BNF<br />

– Summary of Product Characteristics (www.medic<strong>in</strong>es.ie)<br />

– Peer-reviewed journals<br />

– Drugs and Therapeutics Bullet<strong>in</strong> (NHS)<br />

– National Medic<strong>in</strong>es Information Centre (NMIC: SJH website)<br />

– Irish Medic<strong>in</strong>es Board (IMB) (www.imb.ie)<br />

– Guidel<strong>in</strong>es – e.g. NICE<br />

How to Write a Prescription<br />

• Write a prescription for a simple analgesic.<br />

How to Write a Prescription<br />

• Must Conta<strong>in</strong>:<br />

– Date<br />

– Doctor’s details (or the <strong>in</strong>stitution where s/he works)<br />

– Patient<br />

• Name<br />

• Address<br />

• Age if


How to Write a Prescription<br />

• Abbreviations<br />

– O.D. Omni die<br />

– B.D. Bis die<br />

– T.D.S. Ter die sumendus<br />

– Q.D.S. Quarter die sumendus<br />

– P.R.N. Pro re nata<br />

– Nocte / Mane / Tarde<br />

– P.O. Per orum<br />

– P.R. Per rectum<br />

– I.M. Intramuscular<br />

– STAT<br />

How to Write a Prescription<br />

• Category II Drugs – Schedule of Controlled Drugs<br />

– Schedule 1<br />

• Common illicit substances with no medic<strong>in</strong>al effects – LSD, cannabis,<br />

coca leaf. They cannot be generally prescribed.<br />

– Schedule 2<br />

• Most opiate analgesics – their use is characterised by the care required to<br />

achieve a balance between their def<strong>in</strong>ite cl<strong>in</strong>ical benefits, and their<br />

potential for abuse. E.g. morph<strong>in</strong>e sulphate, physeptone, hero<strong>in</strong>, coca<strong>in</strong>e.<br />

– Schedule 3<br />

• Some sedatives e.g. midazolam and temazepam, strong analgesics,<br />

barbiturates<br />

– Schedule 4<br />

• Most other sedatives belong<strong>in</strong>g to the BZ group. Other drugs with a<br />

reduced content of barbiturates<br />

– Schedule 5 (m<strong>in</strong>imal potential for abuse)<br />

How to Write a Prescription<br />

• Controlled Drug Prescription<br />

– Must be handwritten, not typed / computer pr<strong>in</strong>ted<br />

– The drug formulation must be specified – tablets, syrup etc<br />

– Strength and quantity of the medication must be prescribed <strong>in</strong><br />

words and figures<br />

• E.g: morph<strong>in</strong>e slow release tablets 10 mg (ten milligrams); mitte 60<br />

(sixty) tablets<br />

– Cannot be repeated, and must be dispensed with<strong>in</strong> 14 days<br />

Influences on <strong>Prescrib<strong>in</strong>g</strong><br />

• Despite the known tenets of rational prescrib<strong>in</strong>g,<br />

doctors often prescribe without proof of efficacy –<br />

Why<br />

– Doctor Reasons<br />

• True variations <strong>in</strong> medical op<strong>in</strong>ion (Germany 154,000 Rx for HTN<br />

per 1M pop; UK much less)<br />

• The pressure of pharmaceutical advertis<strong>in</strong>g<br />

• Habit, peer group recommendation and ignorance<br />

• F<strong>in</strong>ancial considerations<br />

– Patient Reasons<br />

• Patient demands / expectations (usually overestimated – a larger %<br />

leave with a Rx than expected one. Up to 20% of pts don’t fill Rx)<br />

• F<strong>in</strong>ancial considerations<br />

• Patient knowledge (armed with reams of <strong>in</strong>fo off the Internet)<br />

• GMS v. private (Ireland)<br />

Influences on <strong>Prescrib<strong>in</strong>g</strong><br />

• Social Reasons<br />

– To play for time (until true picture becomes clearer or natural<br />

recovery occurs)<br />

– To cover uncerta<strong>in</strong>ty, rather than admit it<br />

– Medico-legal worries<br />

– To keep faith with patients, to justify their efforts, and to<br />

demonstrate concern<br />

– To avoid confrontation<br />

– To end a consultation<br />

– To keep faith with partners (“Friday afternoon ABx”)<br />

– Attempt at “placebo prescrib<strong>in</strong>g”<br />

– Many patients are adept at secur<strong>in</strong>g social prescriptions –<br />

barga<strong>in</strong><strong>in</strong>g, <strong>in</strong>sistence, flattery, comparison with other doctors<br />

Placebo <strong>Prescrib<strong>in</strong>g</strong><br />

• Placebo Response<br />

– 30-40% response rate<br />

– In some studies, certa<strong>in</strong> personality traits (e.g. sociability,<br />

neuroticism) identify those that respond better<br />

– In other studies there is no l<strong>in</strong>k to personality, and they feel that<br />

most people can respond given the correct situation<br />

– Males tend to respond more frequently than females and higher<br />

SEG’s are especially prone<br />

– Not entirely a psychological response: physiological changes<br />

have been observed – lowered blood sugars, lowered BP,<br />

reduced cholesterol (and CVD mortality <strong>in</strong> one study!)<br />

– Their time-response mimics pharmacok<strong>in</strong>etics of active drugs<br />

– Up to 40% of patients experience side fx<br />

4


Placebo <strong>Prescrib<strong>in</strong>g</strong><br />

• Factors Affect<strong>in</strong>g Placebo Response<br />

– Pa<strong>in</strong> levels – more severe means response more likely<br />

– Anxiety levels<br />

– Tablet size, appearance and formulation. Effective placebos are:<br />

• Either very large or very small<br />

• Unlike an everyday medication <strong>in</strong> appearance<br />

• Capsules / <strong>in</strong>jections rather than tablets<br />

• Bitter to taste<br />

• Colour is also important<br />

– Patient expectation<br />

– High technology: attendance at OPD, X-rays and especially<br />

<strong>in</strong>vasive <strong>in</strong>vxns have a therapeutic effect<br />

– Conviction and charisma of prescriber<br />

Placebo <strong>Prescrib<strong>in</strong>g</strong><br />

• Effect of Drug Colour on Placebo Response<br />

– Colour Best Response In<br />

– Blue / green Creams / o<strong>in</strong>tments<br />

– Green Anxiety<br />

– Red Analgesia<br />

– Red / brown Elixirs<br />

– Yellow Depression<br />

Placebo <strong>Prescrib<strong>in</strong>g</strong><br />

• Ethical Problems<br />

– For:<br />

• It is effective (does the mechanism matter if the result is satisfactory)<br />

• It is reassur<strong>in</strong>g and helps morale <strong>in</strong> chronic / <strong>in</strong>curable disease<br />

• It fulfils patient expectations<br />

• There is no significant toxicity<br />

• There is evidence of an underly<strong>in</strong>g physical basis (e.g. naloxone has been<br />

shown to reverse placebo-<strong>in</strong>duced pa<strong>in</strong> relief - endorph<strong>in</strong>-based mech)<br />

– Aga<strong>in</strong>st<br />

• It is deception and an abuse of a relationship of mutual trust<br />

• It may generate hurt and ill-feel<strong>in</strong>g if the deception is uncovered<br />

• It delays true diagnosis<br />

• It re<strong>in</strong>forces the sick role<br />

Self-Medication<br />

– Conscious effort <strong>in</strong> last decade to <strong>in</strong>crease range of drugs<br />

available OTC. Drugs can be reclassified as OTC provided they<br />

are safe, of low toxicity <strong>in</strong> OD and used only for “m<strong>in</strong>or” selflimit<strong>in</strong>g<br />

conditions<br />

• Advantages<br />

– Opportunity for pts to take more responsibility for their health<br />

– Can save cost, <strong>in</strong>convenience and time <strong>in</strong> gett<strong>in</strong>g a Rx<br />

– Can ease pressures on surgery appts<br />

Self- Medication<br />

• Disadvantages<br />

– Increased risk of drug <strong>in</strong>teraction with prescription meds<br />

– Increased risk of self-medication of side fx<br />

– Risk of <strong>in</strong>appropriate self medication<br />

• Serious illness – may mask / delay presentation<br />

• Tak<strong>in</strong>g the wrong preparation / formulation<br />

• Tak<strong>in</strong>g the wrong dose (or the right dose for too short / long)<br />

– Risk of generat<strong>in</strong>g a “pills for all ills” culture <strong>in</strong> consumers<br />

– Less feedback on adverse drug rxns<br />

– Less chance to offer opportunistic health promotion activities<br />

Doctors need to always ask patients about their use of OTC and<br />

alternative medications, and educate patients on their safe use<br />

Adherence (Compliance)<br />

• The Problem of Non-Adherence (Concordance)<br />

– 1/3 of patients take their drugs exactly as prescribed<br />

– 1/3 take their drugs, but not exactly as prescribed<br />

– 1/3 do not take their drugs<br />

– 50% of the time patient adherence is sufficient to ga<strong>in</strong><br />

therapeutic benefit…….50% of the time it is not<br />

• Conscious / unconscious<br />

• Reflects communication<br />

• Doctor controls prescrib<strong>in</strong>g, but patient controls use<br />

5


Adherence<br />

• Factors Affect<strong>in</strong>g Adherence (Patient / Doctor Factors)<br />

– Understand<strong>in</strong>g of the <strong>in</strong>structions<br />

• Age of patient<br />

• Educational level of patient<br />

• Complexity of regimen etc. (e.g. COCP, bisphosphonates)<br />

– Quality of doctor-patient <strong>in</strong>teraction<br />

– Family and social isolation<br />

– Beliefs, attitude and personality<br />

• Health belief model<br />

• Locus of control<br />

• Ego strength<br />

• Drug aversion<br />

Adherence<br />

• Factors Affect<strong>in</strong>g Adherence (Illness / Medication<br />

Factors)<br />

– Number of medications prescribed concurrently<br />

– Nature of illness<br />

• Asymptomatic<br />

• Psychiatric<br />

• Chronic<br />

– Use of medic<strong>in</strong>e for prevention rather than treatment<br />

– Number of troublesome side fx with the medic<strong>in</strong>e<br />

– Duration of therapy<br />

Adherence<br />

• Ways to Improve Adherence<br />

– Involve the patients and carers <strong>in</strong> the management<br />

– Choose the simplest regime possible<br />

• E.g. once weekly dos<strong>in</strong>g for bisphosphonates<br />

– Discuss the rationale fully<br />

– Simple written <strong>in</strong>structions<br />

– Review risk : benefit balance<br />

– Consider alternatives<br />

– Use expertise of local pharmacist<br />

– Monitor treatment<br />

• Review regularly re side fx etc. and adjust regime accord<strong>in</strong>gly<br />

Adherence<br />

• What should patients be told about their medication<br />

– The name of the medic<strong>in</strong>e<br />

– What it is for<br />

– How it works (or is thought to work)<br />

– Whether it is essential, important, or optional<br />

– How much to take, how to take, how often to take it and how<br />

long to take it for<br />

– What benefits to expect<br />

– What adverse effects might occur<br />

• Legal obligation to tell patients about common side fx and those that are<br />

potentially serious (even if rare) – <strong>in</strong>formed consent<br />

– What to do if no benefit, or less than expected benefit<br />

– What to do if adverse effects occur<br />

Special Circumstances<br />

• Special considerations are needed when prescrib<strong>in</strong>g for<br />

the follow<strong>in</strong>g patient groups:<br />

– The elderly<br />

– Children<br />

– Pregnant (or potentially pregnant) women<br />

– Breast-feed<strong>in</strong>g women<br />

– Term<strong>in</strong>al care<br />

– Co-exist<strong>in</strong>g medical conditions e.g. renal / liver failure<br />

– Particular drug categories e.g. warfar<strong>in</strong><br />

The Pharmaceutical Industry<br />

• Relationship between the Pharmaceutical Industry<br />

and doctors has come under <strong>in</strong>creas<strong>in</strong>g scrut<strong>in</strong>y<br />

– Irish Medical Council issued guidel<strong>in</strong>es <strong>in</strong> 2004<br />

• “Non-promotional educational grants represent the only<br />

acceptable mechanism of f<strong>in</strong>ancial support by the<br />

pharmaceutical and medical manufactur<strong>in</strong>g <strong>in</strong>dustries to<br />

<strong>in</strong>dividual doctors”<br />

– Pros:<br />

• The <strong>in</strong>dustry conducts almost all the research and<br />

development <strong>in</strong>to new drugs, that goes on <strong>in</strong> the world<br />

• Provide <strong>in</strong>formation and education to healthcare workers<br />

• Support the economy<br />

6


The Pharmaceutical Industry<br />

• Cons:<br />

– Doctors prescrib<strong>in</strong>g is <strong>in</strong>fluenced by their <strong>in</strong>teractions with the <strong>in</strong>dustry –<br />

even down to accept<strong>in</strong>g simple gifts like pens etc (sense of obligation,<br />

familiarity with drug)<br />

– Doctors consistently underestimate how much this <strong>in</strong>fluence affects them<br />

personally<br />

– Patients generally are not aware of the l<strong>in</strong>ks between doctors and the<br />

<strong>in</strong>dustry. Studies have shown that when they f<strong>in</strong>d out, they do not approve<br />

– Studies conducted by pharmaceutical companies are often only published if<br />

the results are positive for them<br />

– Information from reps can be <strong>in</strong>accurate – one study found that 11% of<br />

statements made by reps directly contradicted the known facts about a drug<br />

(<strong>in</strong>clud<strong>in</strong>g their own promotional material)<br />

– The pharmaceutical <strong>in</strong>dustry spends billions of euro a year on market<strong>in</strong>g to<br />

doctors – because it works<br />

– Ref: www.nofreelunch.org BMJ 2003;326 31 st May (feature edition)<br />

Case Studies<br />

• 2 y.o. girl<br />

– Fever and refus<strong>in</strong>g all food and dr<strong>in</strong>k x 24 hours<br />

– Severe tonsillitis<br />

Case Studies<br />

• 17 y.o. boy<br />

– Fever and unable to take food and dr<strong>in</strong>k x 24 hours<br />

– Severe tonsillitis<br />

Case Studies<br />

• 47 y.o. man<br />

– BP 168/96<br />

– What do you want to know<br />

– Would you treat him<br />

– What would you use<br />

Case Studies<br />

• 79 y.o. lady <strong>in</strong> nurs<strong>in</strong>g home, asked to come and r/v re<br />

dizz<strong>in</strong>ess and recurrent falls<br />

– Medications<br />

• Madopar 250 QID (levodopa 200mg + benserazide 50mg)<br />

• Digox<strong>in</strong> 0.125mg BD<br />

• Allopur<strong>in</strong>ol 200mg BD<br />

• Frusemide 20mg BD<br />

• Thioridaz<strong>in</strong>e 50mg TID<br />

• Amitryptill<strong>in</strong>e 75mg nocte<br />

• Nitrazepam 5mg nocte<br />

– What might be the <strong>in</strong>dications for these medications<br />

– What are their common adverse effects<br />

– Are any of them likely to be contribut<strong>in</strong>g to her symptoms<br />

– How would you alter her medication.<br />

7


Case Studies<br />

• 50 y.o. male<br />

– Presents with acute muscle spasm of back<br />

– PMHx – mild hypertension, ang<strong>in</strong>a, gout<br />

– Medications<br />

• Aspir<strong>in</strong> 75mg OD<br />

• Centyl K (bendroflumethiazide + K+) 2.5mg OD<br />

• Allopur<strong>in</strong>ol 300mg OD<br />

– What would you consider prescrib<strong>in</strong>g<br />

– Would you have any concerns about his current Rx<br />

Case Studies<br />

• 15 y.o. girl, unaccompanied<br />

– Wants to go on the oral contraceptive pill<br />

– How would you proceed<br />

– What are the ethical issues raised<br />

Conclusion<br />

• Apply cl<strong>in</strong>ical and communication skills<br />

• Apply the pr<strong>in</strong>ciples of rational prescrib<strong>in</strong>g<br />

• Search for objective sources of <strong>in</strong>formation on<br />

medications<br />

• Take steps to maximise adherence<br />

• Review and monitor<br />

8

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!